Enabling Precision Oncology with Next Generation Sequencing Reagents

TOMA’s mission is to provide the most effective sequencing solution to identify clinically meaningful changes in the DNA of cancer tumors.

TOMA has commercially launched TOMA OS-SeqTM Cancer Assay to help laboratories and researchers uncover clinically meaningful genomic changes in tumors, including many missed by other methods.

With an exclusive license to the oligo selective sequencing (OS-Seq) technology invented at Stanford University, TOMA has developed a fast, simple and efficient way to comprehensively analyze all types of tumor samples – even those with limited volume and poor quality.

A team of renowned industry specialists is leading the product development, commercialization and regulatory pathways to bring these products to laboratories, hospital systems and research institutions around the world.


Find Cancer Mutations Using TOMA OS-SeqTM Technology

Breakthrough targeted sequencing technology enables analysis of DNA from archival FFPE tissue and low quantities such as fine needle aspirations, core needle biopsies or plasma (coming soon).

Precision Medicine Webinar Series

Learn the latest in Cancer Genomics

Featured Webinar

Breakthrough Cancer Genomics Sequencing Technology

Featured Webinar

Maximizing Physician Insights with NGS Technologies

Featured Webinar

Experience a Virtual Molecular Tumor Board